Literature DB >> 28027895

Low Level of Blood CD4+ T Cells Is an Independent Predictor of Inferior Progression-free Survival in Diffuse Large B-cell Lymphoma.

Julia Judd1, Essel Dulaimi2, Tianyu Li3, Michael M Millenson4, Hossein Borghaei4, Mitchell R Smith5, Tahseen Al-Saleem2.   

Abstract

BACKGROUND: Tumor-infiltrating immune cells influence diffuse large B-cell lymphoma (DLBCL) outcomes. Relatively little, however, is known about the significance of peripheral blood immune cell numbers on DLBCL behavior. PATIENTS AND METHODS: In the present study, 43 patients with newly diagnosed DLBCL had pretreatment multiparameter peripheral blood flow cytometry performed to assess the immune cell numbers. These cell numbers were correlated with the outcomes of progression-free survival (PFS) and overall survival.
RESULTS: After follow-up period of 0.8 to 152 months (median, 73), 25 patients (56%) were still alive. As continuous variables on univariate analysis, the predictors of PFS were patient age and absolute CD4 cell count (ACD4C), with the International Prognostic Index (IPI) marginally significant. Age was also a significant predictor of overall survival, and the IPI and ACD4C were marginally significant (P = .08). The 17 patients with a greater ACD4C (≥ 450/mm3) had better 5-year PFS than the 26 with a low ACD4C (88% vs. 50%; P = .02). Multivariable analysis, including age as a continuous variable, IPI group, and ACD4C of 450/mm3 showed that age and ACD4C were significant for PFS (P = .01 and P = .02, respectively).
CONCLUSION: Our data, although from a small series, suggest that the blood ACD4C might be a predictor of PFS for patients with DLBCL, independent of age and the IPI.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Flow cytometry; Lymphocyte subsets; Lymphoma prognosis; NK cells; T-cell subsets

Mesh:

Year:  2016        PMID: 28027895     DOI: 10.1016/j.clml.2016.11.005

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  7 in total

1.  Identification of FCER1G related to Activated Memory CD4+ T Cells Infiltration by Gene Co-expression Network and Construction of a Risk Prediction Module in Diffuse Large B-Cell Lymphoma.

Authors:  Xiaoyu Xiang; Li-Min Gao; Yuehua Zhang; Yuan Tang; Sha Zhao; Weiping Liu; Yunxia Ye; Wenyan Zhang
Journal:  Front Genet       Date:  2022-05-30       Impact factor: 4.772

2.  Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms.

Authors:  Alexander W MacFarlane; Ho-Man Yeung; R Katherine Alpaugh; Essel Dulaimi; Paul F Engstrom; Arvind Dasari; Kerry S Campbell; Namrata Vijayvergia
Journal:  Cancer Immunol Immunother       Date:  2021-01-04       Impact factor: 6.630

3.  Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.

Authors:  Kathryn Lurain; Ramya Ramaswami; Ralph Mangusan; Anaida Widell; Irene Ekwede; Jomy George; Richard Ambinder; Martin Cheever; James L Gulley; Priscila H Goncalves; Hao-Wei Wang; Thomas S Uldrick; Robert Yarchoan
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

4.  Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma.

Authors:  Y Kusano; M Yokoyama; Y Terui; N Nishimura; Y Mishima; K Ueda; N Tsuyama; H Yamauchi; A Takahashi; N Inoue; K Takeuchi; K Hatake
Journal:  Blood Cancer J       Date:  2017-04-21       Impact factor: 11.037

5.  High proportion of anergic B cells in the bone marrow defined phenotypically by CD21(-/low)/CD38- expression predicts poor survival in diffuse large B cell lymphoma.

Authors:  Sewa Rijal; Johanna Kok; Caitlin Coombes; Lillian Smyth; Jayde Hourigan; Sanjiv Jain; Dipti Talaulikar
Journal:  BMC Cancer       Date:  2020-11-03       Impact factor: 4.430

6.  Impact of Qi-Invigorating Traditional Chinese Medicines on Diffuse Large B Cell Lymphoma Based on Network Pharmacology and Experimental Validation.

Authors:  Qian Huang; Jinkun Lin; Surong Huang; Jianzhen Shen
Journal:  Front Pharmacol       Date:  2021-12-09       Impact factor: 5.810

7.  An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy.

Authors:  Yaxiao Lu; Jingwei Yu; Wenchen Gong; Liping Su; Xiuhua Sun; Ou Bai; Hui Zhou; Xue Guan; Tingting Zhang; Lanfang Li; Lihua Qiu; Zhengzi Qian; Shiyong Zhou; Bin Meng; Xiubao Ren; Xianhuo Wang; Huilai Zhang
Journal:  Front Oncol       Date:  2021-07-13       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.